Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of BMS-986165 in Healthy Subjects
NCT02534636Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deucravacitinib in psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety of a single oral dose of BMS-986165 at 3 months, Tolerability of a single oral dose of BMS-986165 at 3 months and 2 more. Started Oct 2015; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02534636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534636.